CRISPR Therapeutics AG (CRSP)

Accolade Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	193.62	298.26	389.48	211.89	923.03	1,169
Short-Term Investments	1,528	1,606	1,304	1,603	1,456	521.71
Cash & Short-Term Investments	1,721	1,904	1,694	1,815	2,379	1,690
Cash Growth	-14.01%	12.41%	-6.70%	-23.70%	40.75%	79.10%
Accounts Receivable	-	25	200	-	0.31	0.14
Other Receivables	-	2.1	6.5	11.2	8.4	10.7
Receivables	-	27.1	206.5	11.2	8.71	10.84
Prepaid Expenses	8.93	6.21	7.89	26.01	29.68	15.44
Restricted Cash	3.5	-	-	0.5	-	-
Total Current Assets	1,734	1,937	1,908	1,853	2,418	1,717
Property, Plant & Equipment	262.57	277.55	305.94	320.56	312.04	93.03
Long-Term Investments	22.6	-	1.97	53.13	-	-
Other Intangible Assets	-	-	0.02	0.07	0.13	0.18
Other Long-Term Assets	10.88	27.35	13.57	16.28	22.2	18.14
Total Assets	2,030	2,242	2,230	2,243	2,752	1,828
Accounts Payable	9.75	14.71	38.15	27.43	14.82	9.09
Accrued Expenses	27.37	39.41	40.67	61.33	77.77	54.32
Current Portion of Leases	18.03	17.29	15.63	15.84	12.16	11.36
Current Income Taxes Payable	0.72	0.45	0.44	0.14	0.72	10.47
Current Unearned Revenue	2.13	3.85	4.11	-	1.01	2.34
Other Current Liabilities	46.37	12.08	9.81	16.38	13.4	6.67
Total Current Liabilities	104.36	87.78	108.79	121.11	119.88	94.26
Long-Term Leases	197.43	206.41	223.01	228.18	212.87	50.07
Long-Term Unearned Revenue	12.32	12.32	14.01	12.32	12.32	11.78
Other Long-Term Liabilities	4.48	3.44	0.96	5.97	7.34	7.63
Total Liabilities	318.59	309.95	346.77	367.58	352.42	163.73
Common Stock	2.79	2.7	2.5	2.44	2.39	2.28
Additional Paid-In Capital	3,415	3,294	2,878	2,735	2,598	2,236
Retained Earnings	-1,710	-1,366	-999.7	-846.09	-195.92	-573.58
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06	-0.06
Comprehensive Income & Other	4.04	1.84	1.91	-15.65	-5.07	-0.08
Total Common Equity	1,711	1,932	1,883	1,875	2,399	1,664
Shareholders' Equity	1,711	1,932	1,883	1,875	2,399	1,664
Total Liabilities & Equity	2,030	2,242	2,230	2,243	2,752	1,828
Total Debt	215.45	223.69	238.63	244.02	225.03	61.43
Net Cash (Debt)	1,506	1,680	1,457	1,624	2,154	1,629
Net Cash Growth	-15.48%	15.31%	-10.30%	-24.59%	32.24%	82.77%
Net Cash Per Share	17.52	19.92	18.39	20.89	26.79	24.70
Filing Date Shares Outstanding	90.95	85.77	80.28	78.65	77.07	75.43
Total Common Shares Outstanding	88.38	85.74	80.04	78.51	76.99	73.91
Working Capital	1,629	1,849	1,799	1,732	2,298	1,622
Book Value Per Share	19.36	22.53	23.52	23.89	31.17	22.52
Tangible Book Value	1,711	1,932	1,883	1,875	2,399	1,664
Tangible Book Value Per Share	19.36	22.53	23.52	23.89	31.16	22.51
Machinery	55.15	54.4	53.26	49.62	36.25	29.5
Construction In Progress	5.52	6.12	8.86	6.16	52.4	8.37
Leasehold Improvements	145.85	145.85	143.26	141.68	86.74	25.47

Updated Aug 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q